A Phase 1, Multi-center, Open-label, Single-dose Study to Assess the Pharmacokinetics and Safety of BMS-986435 in Participants With Normal Hepatic Function and Participants With Mild and Moderate Hepatic Impairment
Latest Information Update: 02 Dec 2025
At a glance
- Drugs MYK 224 (Primary)
- Indications Heart failure; Hypertrophic cardiomyopathy
- Focus Pharmacokinetics
- Sponsors Bristol-Myers Squibb
Most Recent Events
- 02 Dec 2025 New trial record